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Summary 
Objective: 
Fibroblast growth factor 21 (FGF21) improves glucose and lipid metabolism but high circulating 
levels are found in type 2 diabetes, suggesting FGF21 resistance. Serum FGF21 predicts incident 
diabetes but its performance, compared to established and emerging predictors, is not known. We 
aimed to study the performance of FGF21 in diabetes prediction, relative to other adipokines and 
established risk factors including 2-hour plasma glucose (2hG) during the oral glucose tolerance test 
(OGTT).  
Design/Participants/Measurements: 
We studied 1380 non-diabetic subjects from the Hong Kong Cardiovascular Risk Factor Prevalence 
Study using the second visit (2000-2004) as baseline when serum levels of FGF21 and other 
adipokines were measured. Glycaemic status was assessed by OGTT. Incident diabetes was defined as 
fasting glucose level (FG) ≥ 7 mmol/L or 2hG ≥ 11.1 mmol/L or use of anti-diabetic agents, at 
subsequent visits. 
Results: 
123 participants developed diabetes over 9.0 years (median). On multivariable logistic regression 
analysis, FGF21 (p=0.003), adipocyte-fatty acid binding protein (p=0.003) and adiponectin (p=0.035) 
were independent predictors of incident diabetes. FGF21 had the best change in log likelihood when 
added to a diabetes prediction model (DP) based on age, family history, smoking, hypertension, BMI, 
dyslipidemia and FG. It also improved the area under ROC curve (AUROC) of DP from 0.797 to 
0.819 (P=0.0072), rendering its performance comparable to the "DP + 2hG" model (AUROC=0.838, 
P=0.19).  
Conclusions: 
As a biomarker for diabetes prediction, serum FGF21 appeared to be superior to other adipokines and, 
on its own, could be considered as an alternative to the OGTT. 
 
Word count: 249  
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Introduction 
Fibroblast growth factor 21 (FGF21) is secreted predominantly by the liver but also by other tissues 
involved in glucose and lipid metabolism, such as the adipose tissue, pancreas and skeletal muscle 1, 
with the contribution from the adipose tissue being much increased in obesity.  Multiple beneficial 
effects of FGF21 on insulin sensitivity, glucose and lipid homeostasis have been observed in animal 
models 
2
. FGF21 is possibly also bioactive in humans as treatment of obese diabetic subjects with 
FGF21-based therapies resulted in beneficial effects on body weight, plasma lipoprotein profile and 
serum adiponectin levels 
3, 4
, and reduced fasting insulin 
3
. Circulating FGF21 levels, however, were 
elevated in obesity 5, as well as in obesity-related diseases such as dyslipidemia, type 2 diabetes 
(T2DM), non-alcoholic fatty liver disease, carotid atherosclerosis and coronary artery disease 
6-10
.  
Raised serum FGF21 levels in these diseases may represent a compensatory response to the 
underlying metabolic stresses 
1
, including insulin resistance/hyperinsulinemia, or may be secondary 
toFGF21 resistance. Indeed, impaired FGF21 signalling in adipocytes has been demonstrated in mice 
with diet-induced obesity 
11
. The above clinical observations have suggested the potential role of 
FGF21 as a biomarker for obesity-related diseases. Notably, high serum FGF21 levels have been 
shown to predict the development of T2DM in two 5-year prospective studies 
12
. 
The dysregulated secretion, and hence altered circulating levels of various adipokines in obesity 13, 
has raised the possibility that serum levels of such adipokines can be used as biomarkers of obesity-
related diseases such as T2DM. In the ARIC study of 4 US communities, it was found that the 
measurement of adiponectin and leptin, but not interleukin-6 and retinol acid binding protein 4, could 
provide a modest improvement on the prediction of T2DM by conventional risk factors 14. In the 
Chinese population, we previously found that adiponectin, tumour necrosis factor-alpha (TNF-α) or 
its soluble receptor tumour necrosis factor-alpha receptor 2 (TNF-α R2), and adipocyte fatty acid 
binding protein (A-FABP), could all independently predict incident diabetes 
15, 16
. We also found that 
the combined use of serum adiponectin and TNF-α R2 levels, when added to conventional risk factors, 
had comparable performance to 2-hour plasma glucose (2hG) during the oral glucose tolerance test 
(OGTT), in predicting incident diabetes 15. With the increasing information on FGF21 as a metabolic 
regulator in humans 
3, 4
 and its role as a novel biomarker for predicting T2DM 
8, 12
, it appeared timely 
that we should assess its performance in the prediction of incident diabetes, in comparison to other 
adipokines  and established predictors of T2DM, including the OGTT. This was conducted using the 
9-year prospective data from the Hong Kong Cardiovascular Risk Factor Prevalence Study (CRISPS).    
Materials and Methods: 
Subjects were recruited from CRISPS, a long-term, population-based, prospective study on the 
development of cardiovascular risk factors in Hong Kong. In 1995-1996 (CRISPS1), 2,895 unrelated 
Chinese subjects were invited randomly by their telephone numbers to undergo a detailed assessment 
Page 3 of 17 Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
17. Subjects returned for reassessment visits in 2000-2004 (CRISPS2), 2005-2008 (CRISPS3) and 
2010-2012 (CRISPS4). Details of medical history taking, anthropometric and biochemical parameters 
measurements were described elsewhere 18. Subjects attended the visits in the morning and all blood 
taking was performed at 9am after an overnight fast to avoid the effect of diurnal changes and meals 
on circulating level of the adipokines 19. Serum levels of the adipokines potentially predictive of 
T2DM were measured from stored serum samples collected at CRISPS2 hence this visit was used as 
the baseline of the current study. Subjects who had been started on anti-diabetic medications, or with 
fasting glucose (FG) ≥ 7 mmol/L or 2-hG ≥ 11.1 mmol/L were considered to have diabetes. Subjects 
without diabetes at baseline visit were followed for their glycemic status at CRISPS3 and CRISPS4. 
The incident diabetes group included all subjects with incident diabetes when screened at CRISPS3 or 
CRISPS4, whilst subjects in the non-diabetes group were those who remained non-diabetic at 
CRISPS4. Hypertension was defined as systolic blood pressure ≥ 140 mmHg, diastolic blood pressure 
≥ 90 mmHg, or on hypertensive treatment. The presence of dyslipidaemia was defined as: 
triglycerides ≥ 1.7mmol/L, HDL cholesterol < 1.0 mmol/L for men and 1.3 for women; LDL 
cholesterol ≥ 3.4mmol/L, or on lipid-lowering treatment. Insulin resistance was estimated using the 
homeostasis model assessment index of insulin resistance (HOMA-IR), calculated by the formula (FG 
in mmol/L x fasting insulin in mIU/L /22.5). The study was approved by the ethics committee of the 
Faculty of Medicine, University of Hong Kong. Informed consent was obtained from all subjects.  
Detailed information on the measurement of serum A-FABP, TNF-α R2 and total adiponectin levels 
were described previously 
15
. TNF-α–R2 was measured as a surrogate marker for TNF-α because 
soluble TNF-α–R2 can be measured in frozen plasma with greater sensitivity and reliability than 
TNF-α 
20
. Serum leptin was measured using a commercial ELISA kit (BioVendor Laboratory 
Medicine, Brno, Czech). Serum FGF21 was measured with an in-house ELISA kit (Antibody and 
Immunoassay Services, University of Hong Kong) as previously described 
5, 8, 21
. The intra- and inter-
assay variations were 4.5% and 6.8% respectively.  
All statistical analyses were performed with SPSS Statistics 19 (SPSS, Chicago, IL). Results were 
presented as mean ± SD or median with interquartile range (IQR) as appropriate. For data that were 
not normally distributed, natural logarithmic transformation was applied before analyses. In univariate 
analyses, variables were compared between groups by one-way ANOVA for continuous data and Chi-
square test for categorical data respectively. Biomarkers including A-FABP, adiponectin, leptin and 
TNF-α R2 with circulating levels showing gender-specific dimorphisms were sex-adjusted. They were 
categorised as high or low level with reference to their optimal cut-offs identified by Youden index 
22
. 
Multivariable logistic regression was used to test for significant independent variables for incident 
diabetes. To compare the relative performance of biomarkers, a basic model based on conventional 
risk factors and common biochemical parameters, which were independent predictors or of clinical 
relevance, was constructed. Log-likelihood ratio tests were used to compare the change in log 
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likelihood (-2LL) before and after addition of biomarkers to the basic model using multivariable 
logistic regression analysis. The biomarker with the best -2LL was tested for the change in the area 
under the curve of receiver operating characteristics (AUROC) when added to the basic model and 
compared with the AUROC with 2hG added to the basic model. Differences in AUROC were 
assessed using Delong’s test 23.  
 
Results 
123 subjects developed incident diabetes over a median of 9.0 years (IRQ: 6.6 – 9.7). Those who 
developed diabetes were older, with higher body mass index (BMI), waist circumference (WC), FG, 
fasting insulin and HOMA-IR (all p<0.001) at baseline visit. More of them were had a history of 
smoking, family history of diabetes (both p=0.005), central obesity, hypertension and dyslipidaemia 
(all p<0.001). The levels of all biomarkers were significantly different between the incident diabetes 
and non-diabetes group in univariate analysis (Table 1). The optimal cut-offs of the biomarkers were 
as follows: 178.2 pg/mL for FGF21; 29.8 ng/mL in men and 22.4 ng/mL in women for A-FABP; 6.19 
µg/mL in men and 6.03 µg/mL in women for adiponectin; 2051.1 ng/ml in men and 2134.6 ng/ml in 
women for TNF-α R2; 4.666 ng/mL for men and 10.227 ng/mL for women for leptin. On multiple 
logistic regression analysis, smoking history, family history of diabetes, WC and BMI were the 
clinical parameters independently predictive of diabetes, whilst FG was the independent biochemical 
predictor. Of the biomarkers, high FGF21 and A-FABP, but not TNF-α R2 and leptin, were 
independent predictors of diabetes, whereas high adiponectin was associated with a reduced risk of 
incident diabetes (Table 2). Addition of FGF21 to the basic diabetes prediction model (DP) consisting 
of age, smoking history, BMI, family history, hypertension, dyslipidaemia and FG resulted in the best 
-2LL of the model, followed by A-FABP and adiponectin, whilst addition of TNF-α R2 or leptin did 
not result in significant changes in -2LL (Table 3). The AUROC of using FGF21 alone in diabetes 
prediction was 0.708. When added to DP, the model consisting of established diabetes risk factors, 
FGF21 significantly improved the AUROC of DP from 0.797 to 0.819 (p=0.0072). Likewise, 2hG 
significantly improved the AUROC of DP to 0.838. However, there was no significant difference 
observed in the AUROC of the two models: “FGF21+DP” versus “2hG+DP” (0.819 vs. 0.838, 
p=0.19) (Table 4, Figure 1). Using FGF21 levels in the form of continuous data instead of applying 
the cut-off value did not affect the results (Table 3 & 4). Addition of adiponectin or A-FABP to the 
same DP model did not show significant improvement in the AUROC (Table 4). In our previous 
report, the combination of ADP + TNF-α R2 had a significant improvement when added to the basic 
model 15. However, in this cohort with a longer follow up duration and more cases of incident 
diabetes, adding the same combination of biomarkers to the DP did not show significant improvement 
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in AUROC (0.807 vs. 0.797, P=0.09), in keeping with the superior predictive performance of serum 
FGF21 as a biomarker of incident diabetes, even when used on its own.    
 
Discussions 
It has been well proven that development of diabetes can be effectively delayed or prevented in a cost-
effective manner in high risk subjects with impaired glucose tolerance 
24
. Despite requiring the 
inconvenient and cumbersome OGTT, 2hG remains a very strong predictor for diabetes development, 
which predicts diabetes on its own and provides additional value to other prediction models 
15, 25
. In 
this paper, we showed that FGF21, a novel metabolic regulator of glucose and lipid metabolism and a 
potential therapeutic agent for metabolic disorders, could also be a useful biomarker for the prediction 
of incident diabetes. As a single biomarker, it enhanced significantly the prediction of diabetes 
development by established risk factors, with a performance that was comparable to 2hG, and 
appeared to be superior to other adipokines previously studied in our CRISPS cohort. 
Obesity indices are good predictors of incident diabetes. Simple diabetes prediction models usually 
rely on obesity indices as their prerequisite parameters. In our cohort, the obesity indices, BMI and 
WC, were also independent predictors. It is however noteworthy that only 20% or fewer obese white 
people will progress to diabetes over subsequent years 26. Likewise, in this long term prospective 
Chinese cohort, only 12.1% subjects with BMI ≥ 23 and 20.5% of subjects with BMI ≥ 27.5 
developed diabetes in 9 years’ time. Hence prediction models usually also include other parameters to 
improve the overall performance. In the basic model we constructed for testing the performances of 
different biomarkers, we did not include both BMI and WC because of their strong correlation. BMI 
was preferred to WC in the model because the measurement of body weight and height should be 
more precise than WC, which is heavily influenced by the anatomic location of measurement 27. 
Taking our basic model as an example, incorporation of other clinical risk factors, like age, 
hypertension, family history, smoking history as well as readily measurable metabolic parameters, 
including fasting glucose and lipid profiles to BMI, already resulted in a reasonably good predictive 
model with an AUROC at 0.797. Hence it has been argued that a prediction model based on simple 
and clinically available variables might do even better than performing the OGTT 
25
. In our cohort, 
however, the addition of the 2hG measurement to the multivariable model, which included FG and 
dyslipidaemia in addition to clinically available risk factors, still further increased the AUC of the 
prediction model, in this and a previous study 15. On the other hand, being an inconvenient test lacking 
in reproducibility, the OGTT is far from ideal as a screening tool and a replacement with comparable 
predictability of diabetes should be most welcome. We did demonstrate in our previous study with a 
shorter follow up period and fewer incident diabetes cases, that the addition of a combination of two 
obesity-related biomarkers, namely adiponectin and TNF-α R2, could be comparable to 2hG in 
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improving diabetes prediction by established risk factors, dyslipidaemia and FG 15. These 
observations may suggest that 2hG remains a strong predictor for future diabetes because it represents 
the part of pathophysiology of T2DM that cannot be reflected by FG, but can be attributed at least 
partially to the effects of circulating adipokines. The findings in the current study suggest that FGF21, 
as a single obesity-related biomarker, appears to have a prediction performance that is closest to 2hG, 
compared to others that have been studied in our population. 
FGF21 has multiple beneficial effects on insulin sensitivity, glucose and lipid homeostasis in animal 
models. However, raised FGF 21 levels have been generally observed in obesity and conditions 
associated with obesity or increased insulin resistance. While insulin resistance is well known to 
appear before the onset of diabetes, FGF21 resistance also precedes dysglycaemia (7, 12). The raised 
FGF21 levels in these conditions may be due to a compensatory response to metabolic stresses 
resulted from increased circulating free fatty acids and insulin, which are known to stimulate 
increased FGF21 expression 1. Moreover, the adipose tissue inflammation in obesity subjects which 
involves the c-Jun NH2-terminal kinase 1 pathway could result in the suppression of β-Klotho 
expression by TNF-α and hence impaired FGF21 action in adipocytes 11. FGF21 is also the upstream 
regulator of adiponectin. It induces expression and secretion of adiponectin in adipocytes to confer the 
glucose-lowering and insulin-sensitizing effects 28. Hence FGF21 resistance in obesity can potentially 
lead to insulin resistance through hypoadiponectinaemia. Whereas the role of hypoadiponectinaemia 
in diabetes development is well established 13-15, the mechanism linking A-FABP with glucose 
homeostasis is less clear. A recent study, however, has demonstrated that A-FABP is a secreted 
adipokine regulating hepatic glucose production, and its immune-neutralization in vivo led to reduced 
gluconeogenesis and the correction of diabetic phenotype in obese mice 
29
. Our study suggested that 
leptin and TNF-α, both pro-inflammatory adipokines with increased expression in obesity 13, are not 
by themselves the major players in diabetes development in our cohort. In a nutshell, FGF21 has been 
found to be involved in the interplay with various other hormones in the pathogenesis of T2DM, 
rendering it a good candidate as a biomarker for diabetes prediction and a possible alternative to the 
inconvenient OGTT. FGF21 was also found to be useful as a biomarker in other diseases related to 
obesity. Serum FGF21 levels were found to be significantly increased in non-alcoholic fatty liver 
disease and were positively correlated with intrahepatic triglyceride. Measurement of FGF21 might 
have the additional benefit of detecting mild steatosis, while the diagnostic sensitivity of 
ultrasonography decreased sharply if the degree of steatosis was less than 30% on biopsy 30. There 
may be additional advantage of measurement of FGF21 in assessing or predicting other diseases 
related to obesity and insulin resistance.  
Our study has the strengths of being a long-term study with prospective data on incident diabetes over 
9 years in a genetically homogenous Chinese population. Our findings should be of considerable 
value in diabetes prediction in the populous major cities of Mainland China. The glycaemic status of 
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all participants, except those who had been taking anti-diabetic agents, was reliably verified by 
OGTT.  We did not use HbA1c as a diagnostic criterion for diabetes as the diagnostic criteria have 
changed over time with the HbA1c criterion only being accepted after 2011. Had the HbA1c criterion 
been adopted, an additional number of subjects would have been screened to have diabetes as shown 
by our results at CRISPS4 31. On the other hand, the data of this paper is also limited by the drawback 
of a very long-term prospective study as we unavoidably had participants lost to follow up due to 
various reasons. Participants who returned for follow-up visits up till CRISPS4 might well be the 
more health conscious subjects and might not be truly representative of the general population. 
Application of the FGF21 level for diabetic risk prediction requires integration with other risk factors 
to formulate a risk score which requires multi-steps calculations and may be inconvenient to use when 
compared with prediction models based on simple measurable parameters. However, this clumsy 
calculation procedure is not difficult to overcome due to the relatively easy accessibility to computers 
or even smartphones nowadays. Lastly, our participants were middle-aged individuals with a mean 
age of 50.3 and the youngest participant was 30 years old at CRISPS2 baseline. Our conclusions may 
not be applicable to younger individuals.   
In summary, we have demonstrated that, as a single biomarker, FGF21 adds value to established risk 
factors when used in the construction of diabetes prediction models. In this regard, its performance 
appears to be superior to other obesity-related biomarkers and is comparable to the 2-hour post OGTT 
glucose. Further studies in other populations are warranted to validate its use as a biomarker to 
identify high risk subjects for interventional measures to prevent diabetes development.  
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Figure legends 
Figure 1 Comparisons of AUROCs of different diabetes prediction models. 
A: Diabetes Prediction Model (DP) based on Age, body mass index, family history of diabetes, ever 
smoking history, hypertension, fasting glucose and dyslipidaemia; B: DP + 2h-Glucose; C: DP + 
FGF21 (with cut-off); D: FGF21 (continuous data); FGF21, fibroblast growth factor 21 
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Table 1  Baseline clinical and biochemical characteristics of subjects with and without incident 
Type 2 diabetes in 9.0 (6.6-9.7) years 
Baseline variables Cumulative DM Non-DM p-value 
N 123 1257 -- 
Age, years 55.2±10.4 49.8±10.9 <0.001 
Men, % 51.6 44.7 0.139 
Ever smoker, % 34.7 23.4 0.005 
Physical activity, % 30.8 27.4 0.430 
Family history of diabetes, % 25.8 16.0 0.005 
    
Central Obesity, % 47.6 23.4 <0.001 
Waist circumference, cm   <0.001* 
   Male 88.5±8.89 82.8±8.31  
   Female 80.8±9.05 74.7±8.57  
Body Mass Index, kg/m
2
 25.9±3.69 23.6±3.22 <0.001 
    
Hypertension, % 33.9 19.3 <0.001 
Systolic blood pressure, mmHg 128±19 119±17 <0.001 
Diastolic blood pressure, 
mmHg 
79±9 74±10 <0.001 
    
IGT/IFG, % 66.9 22.9 <0.001 
Fasting glucose, mmol/L 5.45±0.58 5.01±0.47 <0.001 
Fasting insulin
†
, mIU/L 8.9 (6.6-15.0) 6.9 (5.0-9.7) <0.001 
HOMA-IR† 2.30 (1.49-2.30) 1.52 (1.11-2.19) <0.001 
    
Dyslipidemia, % 82.3 58.9 <0.001 
Total cholesterol, mmol/L 5.51±1.00 5.24±0.87 0.002 
Triglycerides
†
, mmol/L 1.3 (1.0-2.0) 1.1 (0.7-1.5) <0.001 
HDL cholesterol, mmol/L 1.29±0.33 1.44±0.38 <0.001 
LDL cholesterol, mmol/L 3.50±0.91 3.23±0.77 <0.001 
    
Adiponectin†, ug/ml   <0.001* 
Men 4.53 (3.04-6.06) 5.90 (3.83-9.35)  
Women 7.12 (4.42-11.3) 8.16 (5.76-11.8)  
FGF21
†
, pg/ml   <0.001* 
Men 234.7 (154.1-408.9) 155.3 (84.4-261.3)  
Women 266.6(186.5-322.6) 131.1 (78.1-233.1)  
A-FABP
†
, ng/ml   <0.001* 
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Baseline variables Cumulative DM Non-DM p-value 
Men 21.8 (14.8-31.9) 18.2 (13.2-24.4)  
Women 29.3 (23.4-37.0) 22.0 (16.4-30.3)  
TNF-alpha R2
†
, ng/ml   <0.001* 
Men 2153.8 (1864.4-2654.6) 1934.9 (1683.7-2282.0)  
Women 1897.3 (1557.6-2335.2) 1758.8 (1520.1-2067.4)  
Leptin†, ng/ml   <0.001* 
Men 5.78 (3.21-8.73) 4.01 (2.02-6.48)  
Women 14.4 (10.4-20.7) 11.0 (7.75-15.7)  
    
 
Data was presented as mean ± standard deviation, median (interquartile-range), or percentage as appropriate. 
*Sex-adjusted p-value; †log transformed before analysis. Central obesity was defined as waist circumference ≥ 
90 cm for men and 80 for women; Hypertension was defined as systolic blood pressure ≥ 140 mmHg, diastolic 
blood pressure ≥ 90 mmHg, or on hypertensive treatment. Dyslipidaemia: triglycerides ≥ 1.7mmol/L, HDL 
cholesterol < 1.0 mmol/L for men and 1.3 for women; LDL cholesterol ≥ 3.4mmol/L, or on lipid-lowering 
treatment. 
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Table 2 Multivariable logistic regression for significant independent variables predicted the 
development of DM  
Baseline variables Adjusted OR (95% CI) p-value 
Age (years) 1.02 (1.00-1.04) 0.039 
Ever smoking 1.81 (1.14-2.85) 0.011 
Family history of diabetes 2.37 (1.45-3.85) 0.001 
BMI (kg/m
2
) 1.09 (1.02-1.16) 0.008 
HT (%) 1.10 (0.70-1.72) 0.682 
FG (mmol/L) 3.63 (2.39-5.50) <0.001 
Dyslipidemia 1.61 (0.96-2.71) 0.071 
FGF21 (pg/ml) 1.60 (1.18-2.16) 0.003 
A-FABP* (ng/ml) 2.03 (1.28-3.20) 0.003 
Adiponectin* (ug/ml)
 
 0.62 (0.40-0.97) 0.035 
*Sex specific; BMI, body mass index; HT, hypertension; FG, fasting glucose; FGF21, fibroblast 
growth factor 21; A-FABP, adipocyte-fatty acid-binding protein. 
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Table 3 Log-likelihood ratio tests comparing the change before and after addition of adipokines 
by using multivariable logistic regression analysis 
Diabetes 
Prediction 
Model 
Biomarkers -2LL Change in  
-2LL from 
basic model 
p-value  
Age, FH of DM, 
smoking, BMI, HT, 
FG and dyslipid 
 682.562 --   
 + FGF21  15.070 <0.001  
 + FGF21*  21.805 <0.001  
 + A-FABP*  11.969 <0.001  
 + Adiponectin*  4.323 0.038  
 + TNF-α R2*  1.558 0.212  
 + Leptin*  1.515 0.218  
FGF21 was log-transformed before analysis, unless otherwise specified; *Sex-specific optimal cut-off 
points applied.  
-2LL, -2 log Likelihood; FH of DM, family history of diabetes; smoking, history of ever smoking; 
BMI, body mass index; HT, hypertension; FG, fasting glucose; dyslipid, dyslipidaemia; FGF21, 
fibroblast growth; A-FABP, adipocyte-fatty acid-binding protein; TNF-α R2: tumour necrosis factor-
alpha receptor 2. 
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Table 4 Comparisons of AUROCs of different diabetes prediction models. 
Model Additional variable(s) AUROC (95% CI) Delong p-value 
[Referent:  
Base model] 
Delong p-value 
[Referent:  
2h-Glucose] 
Age, BMI, Fhx of 
DM, Ever smoking, 
HT, FG and Dyslip 
-- 0.797 (0.773-0.817) Referent -- 
 + 2h-Glucose  0.838 (0.817-0.857) 0.0010 Referent 
 + FGF21 0.813 (0.792-0.833) 0.0083 0.0622 
 + FGF21* 0.819 (0.798-0.839) 0.0072 0.1882 
 + A-FABP* 0.808 (0.786-0.828) 0.0743 0.0290 
 + ADP* 0.799 (0.777-0.820) 0.4319 0.0023 
 + TNF- α R2* 0.804 (0.782-0.825) 0.0782 0.0099 
 + ADP* + TNF- α R2* 0.807 (0.785-0.828) 0.0906 0.0203 
 
FGF21 was log-transformed before analysis, unless otherwise specified; *Sex-specific optimal cut-off 
points applied.  
AUROC, Area under the curve of receiver operating characteristics; BMI, body mass index; HT, 
hypertension; Fhx of DM, family history of diabetes; FG, fasting glucose; dyslip, dyslipidemia; 
FGF21, fibroblast growth factor 21; A-FABP, adipocyte-fatty acid-binding protein; ADP, 
adiponectin; TNF-α R2: tumour necrosis factor-alpha receptor 2. 
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Figure 1 Comparisons of AUROCs of different diabetes prediction models.  
A: Diabetes Prediction Model (DP) based on Age, body mass index, family history of diabetes, ever smoking 
history, hypertension, fasting glucose and dyslipidaemia; B: DP + 2h-Glucose; C: DP + FGF21 (with cut-
off); D: FGF21 (continuous data); FGF21, fibroblast growth factor 21  
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